This note was updated on 12 Jan 2018 to provide links to the videos from the bootcamp sessions. Dear All: GARDP + CARB-X have this week hosted Antibiotic Bootcamps #1, #2, and #3 at the ASM-ESCMID conference on antibiotic R&D. There were nearly 350 people registered for the full meeting with good attendance at each Bootcamp.
Dear All: Building on my recent note about a search for the G20 secretariat lead, we now have CARB-X getting into job creation mode by posting 8 positions across 5 different job openings: Accelerator Lead: coordinates the work of the growing accelerator network for all CARB-X-funded companies. Support Team Lead (three positions): takes responsibility for managing the full range of
Dear All: It is exciting to see that CARB-X today announced that it is seeking to partner with up to 6 additional accelerator organizations to expand its drug development and business support for its growing pipeline of early development antibacterial research projects. The Powered by CARB-X portfolio currently has 22 active projects in its pipeline, with more project announcements
Dear All: The wait is over — CARB-X has today released a call for new applications! The call has an interesting 2-round structure and you’ll need to study carefully both the press release and the supplemental details document to understand where your program would fit. Here’s my summary: Round 1: Submission window for Expressions of Interest: 22-29 March 2018 Scope: Restricted
Dear All: CARB-X has today announced funding of 7 more companies, bringing the total funded portfolio to 17 potential new therapies (or preventatives) and 1 novel point-of-care diagnostic (see graphic above). Befitting the international nature of those of you who read my occasional notes (see map just below), there are now funded companies in 6 countries (US, UK, France,
Dear All: There has been tremendously exciting activity in parallel with this week’s World Health Assembly! Here’s the list… CARB-X has announced this week that the Bill & Melinda Gates Foundation and the UK government will contribute $25 million and £20 million ($26.9 million), respectively, over the next 3 years. With this new inflow of $50m in committed funds,
Dear All: Two things of note this afternoon… First, the previously noted BARDA RFP to acquire biothreat antibiotics is now posted here with submissions accepted through 21 June 2019: “Under this RFP, BARDA plans to support the procurement of antibiotic(s), which will either be delivered to the ASPR/SNS or maintained as VMI, using Project BioShield (PBS) funds. “PBS funds will also support
Dear All, Committing serial email this afternoon… First, the note I just sent on FMT for Clostridium difficile (link) prompted comments that the organism is now called Clostridioides difficile. This name change slipped past me, I’ll admit! But it does seem a settled change … see this helpful editorial from May 2019 in Lancet ID for a summary of how the new
Dear All: CARB-X is looking for you! This new job was just now posted: The Director of R&D is a new senior role on the leadership team of CARB-X, reporting directly to the Executive Director (Kevin Outterson). Here’s the brief: “The Director of R&D will take responsibility for the planning, review, awarding and monitoring of novel R&D projects
Dear All: Two interesting job posts this week. Could one of them be for you? First, CARB-X seeks a Boston-based full-time Chief of R&D (link). This is clearly a very senior role on the CARB-X leadership team: the R&D Chief would have responsibility across the entire CARB-X portfolio for the planning, review, awarding and monitoring of
Using ideas to connect, create, and inspire
Supported by the Wellcome Trust